Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis
The comparison of the two antiviral therapies for the early treatment of COVID-19 did not yield statistically significant differences in the potential efficacy and safety to prevent hospitalisation or serious adverse events. However, the results of the cost-analysis showed a saving in favour of NRM/RTV.
Authors
- Maria Mazzitelli (ORCID: https://orcid.org/0000-0003-0263-0703)
- Ileana Baldi (ORCID: https://orcid.org/0000-0002-8578-9164)
- Francesca Venturini (ORCID: https://orcid.org/0000-0003-0396-4377)
- Daniele Mengato (ORCID: https://orcid.org/0000-0003-1374-1505)
- Honoria Ocagli (ORCID: https://orcid.org/0000-0002-5823-1659)
- Giovanni Chinellato (ORCID: https://orcid.org/0009-0001-7091-8672)
- Giacomo Berti (ORCID: https://orcid.org/0009-0000-8992-1049)
- Anna Maria Cattelan
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fphar.2025.1537018
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.13